Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Co (JP:4502)
:4502
Earnings Data
Report Date
Jan 29, 2026Before Open (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
46.32Last Year’s EPS
15.15Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call reflected a mixed financial performance with strong cash flow and pipeline advancements but was overshadowed by significant challenges such as the VYVANSE generic impact, ENTYVIO's slower growth, and foreign exchange headwinds. The partnership with Innovent Biologics provides a positive outlook for the oncology pipeline, but current financial pressures remain a concern.Company Guidance
Growth in Launch Products
Launch products grew 5.3% at constant exchange rate (CER), representing over 50% of revenue. This growth is expected to accelerate in the second half of the fiscal year.
Strong Free Cash Flow
Adjusted free cash flow was JPY 525.4 billion, including improvements in working capital, indicating strong cash generation despite challenges.
Pipeline Advancements
Positive Phase III studies for rusfertide and oveporexton, with zasocitinib Phase III data expected by the end of the calendar year. The pipeline is further enriched by a strategic partnership with Innovent Biologics.
Innovent Biologics Partnership
The partnership with Innovent Biologics adds cutting-edge assets to Takeda's oncology pipeline, including PD-1/IL-2 alpha bias bispecific and next-generation ADCs.
JP:4502 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
JP:4502 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 30, 2025 | ¥4234.00 | ¥4257.00 | +0.54% |
Jul 30, 2025 | ¥4189.43 | ¥4199.20 | +0.23% |
May 08, 2025 | ¥4218.75 | ¥4183.56 | -0.83% |
Jan 30, 2025 | ¥3972.29 | ¥3998.12 | +0.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Takeda Pharmaceutical Co (JP:4502) report earnings?
Takeda Pharmaceutical Co (JP:4502) is schdueled to report earning on Jan 29, 2026, Before Open (Confirmed).
What is Takeda Pharmaceutical Co (JP:4502) earnings time?
Takeda Pharmaceutical Co (JP:4502) earnings time is at Jan 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Takeda Pharmaceutical Co stock?
The P/E ratio of Takeda Pharmaceutical Co is N/A.
What is JP:4502 EPS forecast?
JP:4502 EPS forecast for the fiscal quarter 2025 (Q3) is 46.32.